News & Events


RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

Seattle, WA, August 26, 2020 – RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer.


RareCyte® announces the Orion spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis

Seattle, WA. July 16, 2020 – RareCyte, Inc., a company focused on providing Precision Biology solutions for life sciences, announced today the Orion spatial biology analysis platform applicable to translational and clinical research. Orion is based on a patented and proprietary technology that will accelerate immuno-oncology and infectious disease research. Orion enables comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment in a matter of hours, in contrast to existing technologies that require several days to weeks.


Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology Applications

Berlin, Germany, Lyon, France, and Seattle, WA, USA, June 22, 2020: SCIENION AG and RareCyte Inc. today announced that cellenONE® proved to be a most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENION’s French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.


RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay

Seattle, WA, February 27, 2020 - RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research.


RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing

SEATTLE, Dec. 19, 2019 - RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its instrument and consumables platform used in research and clinical markets. The $22M investment was led by HealthQuest Capital, with participation from 5AM Ventures and company founder, Ron Seubert.



Joe Victor, RareCyte CEO presented at the Life Science Innovation NW conference July 16 including an announcement of the launch of the breakthrough Orion Spatial Biology platform.